1. Consort Diagram 600 pts with 644 eyes accessed for eligibility
554 pts studied for the effect of time from diagnosis to enucleation on mortality
46 pts met first-round exclusion criteria
44 bilateral pts with each eye group D or E
2 pts died from non-tumor cause
510 pts studied for the effect of pre-enucleation chemotherapy on mortality
44 pts met second-round exclusion criteria
15 pts received pre-enucleation chemo for less than one complete cycle
29 pts received extensive pre-enucleation treatment
177 D Eyes
333 E eyes
3 plaque
6 PPV
18 IAC
1 stem cell
Factors to consider: pathologic staging, time from diagnosis to enu, neoadjuvant chemo, adjuvant chemo
Dependent variable: mortality.
1 immunotherapy

2. Relationship between neoadjuvant chemo cycle and pathology for staged D&E Eyes
Low Risk Pathology (LRP): pT1 and pT2
High Risk Pathology (HRP): pT3 and pT4

3. Relationship between neoadjuvant chemo cycle and mortality
After Controlling for Adjuvant Chemo
(Kaplan Mier Survival Analysis)